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The ProTides Boom
Youcef Mehellou*[a]
Dedicated to Prof. Chris McGuigan (1958–2016)
Phosphate prodrug strategies have been successfully used in
the discovery of various nucleotide therapeutics that are cur-
rently in daily clinical use for the treatment of viral infections,
in particular, hepatitis B and C (HBV and HCV, respectively) and
HIV.[1] Over the last few years, the ‘ProTide’ technology—pio-
neered by Chris McGuigan (Cardiff University, UK)—has
emerged as a powerful strategy in the discovery of nucleotide
therapeutics.[2] Indeed, this technology was used in the suc-
cessful discovery and development of two FDA-approved Pro-
Tides, Sovaldi and tenofovir alafenamide. The pipelines of
several pharma and biotech companies seem to be stocked
with a selection of ProTides, some of which are currently in
phase III clinical trials, while there is an increasing number of
reports on ProTides undergoing preclinical studies. Collectively,
these reflect a ProTides boom that could, in the future, be
translated into the approval of more ProTides to treat viral in-
fections and cancer.
The in vivo activation of many antiviral and anticancer nu-
cleosides involves phosphorylation into their active di- or tri-
phosphate counterparts.[3] Among the three kinase-dependent
phosphorylation steps required for the bioactivation of this
class of therapeutics, the first phosphorylation step that con-
verts nucleosides into their 5’-O-monophosphate derivatives is
often found to be the rate-limiting step.[4] To overcome this in-
efficient activating metabolic step, numerous strategies that
deliver nucleoside 5’-O-monophosphates into cells have been
developed.[1] Nowadays, one of the most applied phosphate
prodrug approaches is the ProTide technology. The develop-
ment[2] of this technology started by masking the 5’-O-mono-
phosphate groups of therapeutic nucleosides with simple dia-
lkyl and then haloalkyl groups. However, these attempts did
not lead to improved biological activity, most likely due to the
inability of these masking groups to be hydrolyzed in vivo to
release the nucleoside monophosphate, which can be subse-
quently further phosphorylated to the active species. Next,
McGuigan and co-workers synthesized alkyloxy and haloalkyl
phosphoramidate prodrugs, and these showed better activities
than their parent nucleosides.[5] This was the first breakthrough
in the development of ProTides and provided evidence that
masking of phosphate groups with biocleavable motifs may
yield an effective prodrug system for the delivery of therapeu-
tic nucleoside monophosphates. These initial studies identified
l-alanine as a superior amino acid in the alkyloxy phosphora-
midates, an observation that has informed recent drug discov-
ery programs that yielded FDA-approved drugs.[5b] Encouraged
by this, the phosphate group was masked with two amino
acid esters. Back then, this was found not to be beneficial as
the prodrugs were largely inactive. Diaryl phosphates were
studied next, and these showed very good activity. Hence, the
McGuigan lab combined the amino acid ester from the alky-
loxy and haloalkyl phosphoramidates and the aryl masking
group to generate aryloxy triester phosphoramidates.[6] These
were found to be superior in the delivery of therapeutic nu-
cleoside 5’-O-monophosphates. Since then, the masking of the
phosphate group with an amino acid ester and an aryl motif,
nowadays known as the ProTide technology, has become an
approved prodrug strategy in the discovery of nucleotide ther-
apeutics. The mechanism by which the ProTides are metabo-
lized in vivo to release the nucleoside monophosphate is be-
lieved to proceed through the action of two enzymes: an es-
terase, such as cathepsin A,[7] and a phosphoramidase-type
enzyme, such as hint-1,[8] as illustrated in Scheme 1.[2]
ProTides as clinical candidates and drugs
To date, at least ten ProTides have reached clinical trials and
have been investigated as treatments for viral infections and
cancer (Figure 1). The McGuigan research group discovered
and developed the anti-HCV agent INX-189, a ProTide of 6-O-
methyl-2’-C-methyl guanosine (1).[9] At that time, this com-
pound was the most potent inhibitor of HCV replication in
cell-based replication assays (EC50=0.01 mm, EC90=0.04 mm,
CC50=7 mm). Critically, it generated significantly higher levels
of the 6-O-methyl-2’-C-methyl guanosine triphosphate than
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The masking of nucleoside phosphate and phosphonate
groups by an aryl motif and an amino acid ester, nowadays
known as the ‘ProTide’ technology, has proven to be effective
in the discovery of nucleotide therapeutics. Indeed, this tech-
nology, which was invented by Chris McGuigan in the early
1990s, has inspired the discovery of two FDA-approved antivi-
ral nucleotide drugs, and many more are currently undergoing
(pre)clinical development. The usefulness of this technology in
the discovery of nucleotide therapeutics is showcased in this
Highlight by discussing the ProTides development and the var-
ious ProTides that have reached clinical trials.
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the parent nucleoside and had a half-life of >24 h. Given the
excellent pharmacokinetics (PK) and pharmacodynamics (PD)
profiles of INX-189, it was chosen as a clinical candidate that
was then developed by Inhibitex Inc.[10] Following successful
early clinical results, INX-189 was acquired by Bristol-Myers
Squibb (BMS) and studied in phase III clinical trials in combina-
tion with daclatasvir, another anti-HCV experimental drug of
BMS. However, cardiotoxicity was observed, and further devel-
opment was suspended.[11]
Other ProTides for the treatment of HCV, particularly PSI-
353661 (2)[12] and PSI-7977 (3),[13] proceeded to clinical evalua-
tion. PSI-353661 is a ProTide of 6-O-methyl-2’-deoxy-2’-fluoro-
2’-C-methylguanosine, whereas PSI-7977 is a ProTide of 2’-
deoxy-2’-fluoro-2’-C-methyluridine. Both compounds showed
potent anti-HCV activity through efficient delivery of the
parent nucleosides 5’-O-monophosphates. As a result of the
impressive early data from the clinical trials of these two
agents, they were acquired by Gilead Sciences, Inc. Out of the
two compounds, PSI-7977, which subsequently became GS-
7977, successfully completed clinical evaluations and became
known as sofosbuvir (SovaldiTM), the first ProTide approved for
clinical use against HCV.
GS-5734 (4)[14] is a C-nucleoside ProTide, which is currently
undergoing phase I clinical trials for the treatment of Ebola.[14]
Preclinical data showed that GS-5734 exerts potent antiviral ac-
tivity against variants of the Ebola virus (EBOV).&&Definition
OK?&& The ProTide showed potent inhibition of EBOV repli-
cation (EC50=0.06 to 0.14 mm), while the parent C-nucleoside
was not as effective (EC50: 0.77 to >20 mm). Impressively, in
rhesus monkeys infected with EBOV, once-daily intravenous ad-
ministration of GS-5734 led to significant suppression of EBOV
replication and 100% protection of infected animals against
lethal disease. GS-5734 also showed promising inhibition of
the replication of other pathogenic RNA viruses, such as arena-
viruses, filoviruses, and coronaviruses, indicating the wide-
spectrum of activity of this ProTide.
GS-7340 (5),[15] a ProTide of the acyclic nucleoside phospho-
nate tenofovir, of which the oral prodrug, tenofovir disoproxil,
Scheme 1. Postulated mechanism of the in vivo metabolism of the ProTides to release nucleoside monophosphates.
Figure 1. Structures of a selection of ProTides that have reached clinical trials and those that have been approved by the FDA.
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is FDA-approved for HIV therapy, exhibited improved anti-HIV
activity and better in vivo stability than tenofovir. Impressively,
the ProTide GS-7340 generated 10- to 30-fold higher levels of
tenofovir and its phosphorylated metabolites following incuba-
tion of peripheral blood mononuclear cells compared with te-
nofovir disoproxil and tenofovir, respectively.[16] Although GS-
7340 is similar to the FDA-approved tenofovir disoproxil, it is
more potent, and thus in phase III clinical studies therapeutic
effects were achieved at lower doses with fewer incidences of
side effects. In late 2015, GS-7340, now known as tenofovir ala-
fenamide, was approved in combination with other anti-HIV
agents for the treatment of HIV-1 infection.
NUC-1031 (6)[17] is an anticancer ProTide that was discovered
by the McGuigan group and is currently being developed by
NuCana Biomed Ltd. It is a prodrug of the FDA-approved anti-
cancer drug gemcitabine (GemzarTM). This compound over-
came three resistance mechanisms that limit the efficacy of the
parent nucleoside gemcitabine. Results from phase I/II clinical
trials showed that NUC-1031 is effective against a wide range
of cancers and was well-tolerated by patients. Impressively, five
out of 68 patients achieved tumor shrinkage of 30%, while
an additional 33 patients had achieved stable disease. NuCana
is also pushing forward the clinical development of NUC-
3373,[18] a ProTide of 5-fluoro-2’-deoxyuridine (FUDR) [structure
not shown].
At least a further four ProTides were reported to have under-
gone clinical evaluation, that is, thymectacin (7) for cancer,
stampidine (8) and GS-9131 (9) for HIV; and GS-6620 (10) for
HCV.
The plethora of ProTides that have been, are still undergo-
ing, or have successfully completed clinical trials clearly high-
lights the effectiveness of this technology to deliver nucleotide
therapeutics. Coupling this to the large number of ProTides
that are currently undergoing preclinical evaluation, it is safe
to say that more ProTides will progress into clinical studies, in-
creasing the chances of more ProTides being approved in the
future to treat viral infections and cancer. This has been made
possible by the pioneering work of Prof. Chris McGuigan that
started in the early 1990s, and which years later yielded the
ProTide technology as we know it today. Since its develop-
ment, the ProTide technology has been widely adopted and
adapted by academic research groups, as well as small and
large pharmaceutical companies to discover new medicines
that have already improved treatment outcomes and conse-
quently the quality of life of many patients.
Keywords: nucleosides · nucleotides · phosphorylation ·
prodrugs · protides
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The ProTides Boom
Nucleotide therapeutics: The phos-
phate and phosphonate ‘ProTide’ tech-
nology, which was invented by the
McGuigan lab in the early 1990s, has
proven to be effective in the discovery
of nucleotide therapeutics. Impressively,
it has already inspired the discovery of
two FDA-approved drugs with many
more in (pre)clinical development.
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